# A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

> **NCT07701993** · PHASE3 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 1740 (estimated)

## Conditions studied

- Metabolic Dysfunction-associated Steatohepatitis

## Interventions

- **DRUG:** Efimosfermin alfa
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07701993
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-22
- **Primary completion:** 2033-06-23
- **Final completion:** 2033-08-24
- **Target enrollment:** 1740 (ESTIMATED)
- **Last updated:** 2026-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07701993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07701993, "A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07701993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*